Melanoma Vaccine Modified To Express Hla A2/4-1Bb Ligand
Metastatic Disease
Hadassah Medical OrganizationvaccinePhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 89/ 100
Competitive context
171 Active assets in the Metastatic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Ruijin Hospital | Phase 4 | BBB |
Eloxatin Ruijin Hospital | Phase 4 | BBB |
Irinotecan Eli Lilly and Company | Phase 4 | BBB |
DEXAMETHASONE Janssen Research & Development, LLC | Phase 2 | BBB |
Ipilimumab 7 Hills Pharma, LLC | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Melanoma Vaccine Modified To Express Hla A2/4-1Bb Ligand is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →